SEC 13F Intelligence

Managers / Q1 2026

Essex Woodlands Management, Inc.

CIK 0001542339 · 21 WATERWAY AVE, STE 150, THE WOODLANDS, TX, 77380 · 281-364-1555

Reported Value
$251M
Q1 2026
Positions
5
Filings on Record
30
2019–present window
Filed
May 4, 2026
original filing

Summary

Essex Woodlands Management, Inc. reported $251M in U.S.-listed holdings across 5 positions for Q1 2026.

The portfolio is heavily concentrated: BVS alone accounts for 47.5% of reported value.

Compared with Q4 2025, the fund opened 0 new positions and exited 1.

Portfolio Metrics

Turnover
+7.8%
vs prior filed quarter
Largest Position
+47.5%
Bioventus

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $251MQ4 ’18Q1 ’19: $201MQ2 ’19: $173MQ3 ’19: $161MQ4 ’19: $214MQ4 ’19Q1 ’20: $155MQ2 ’20: $204MQ3 ’20: $188MQ4 ’20: $385MQ4 ’20Q1 ’21: $640MQ2 ’21: $677MQ3 ’21: $451MQ4 ’21: $445MQ4 ’21Q1 ’22: $414MQ2 ’22: $242MQ3 ’22: $242MQ4 ’22: $179MQ4 ’22Q1 ’23: $173MQ2 ’23: $132MQ3 ’23: $113MQ4 ’23: $404MQ4 ’23Q1 ’24: $345MQ2 ’24: $307MQ3 ’24: $350MQ4 ’24: $433MQ4 ’24Q1 ’25: $347MQ2 ’25: $279MQ3 ’25: $307MQ4 ’25: $318MQ4 ’25Q1 ’26: $251Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 100.0%
  • Common Stock · 100.0% · $251M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
VEROVENUS CONCEPT INCSOLD OUT99.0K0$146,551$0
MDXGMIMEDX GROUP INCHELD+028.20M$80M$111M
BVSBIOVENTUS INCHELD+013.02M+$22M$119M
EYPTEYEPOINT PHARMACEUTICALS INCHELD+01.08M$6M$14M
TELATELA BIO INCHELD+07.71M$4M$5M
4875MEDICINOVA INCHELD+01.11M+$66,356$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

5 positions
#IssuerClass% PortfolioValueShares
1BVSBIOVENTUS INChistory →COM CL A47.45%$119M13.02M
2MDXGMIMEDX GROUP INChistory →COM44.45%$111M28.20M
3EYPTEYEPOINT PHARMACEUTICALS INChistory →COM NEW5.58%$14M1.08M
4TELATELA BIO INChistory →COM1.91%$5M7.71M
54875MEDICINOVA INCCOM NEW0.60%$2M1.11M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$251M5May 4, 202613F-HRchanges · EDGAR ↗
Q4 2025$318M6Feb 4, 202613F-HRchanges · EDGAR ↗
Q3 2025$307M6Nov 12, 202513F-HRchanges · EDGAR ↗
Q2 2025$279M6Aug 7, 202513F-HRchanges · EDGAR ↗
Q1 2025$347M6May 13, 202513F-HRchanges · EDGAR ↗
Q4 2024$433M7Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$350M7Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$307M7Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$345M7May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$404M7Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$113M6Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$132M6Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$173M7May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$179M7Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$242M7Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$242M9Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$414M9May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$445M10Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$451M9Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$677M9Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$640M9May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$385M8Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$188M8Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$204M8Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$155M8May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$214M8Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$161M6Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$173M6Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$201M8May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$251M8Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.